A

Aditxt

D
ADTX
USD
-0.0171
(-4.6849%)
Market Closed
10,105.00
Volume
-91.26
EPS
-
Div Yield
-0.010119
P/E
1,874,723.51
Market Cap
Today
-4.6849%
1 Week
-26.758%
1 Month
-70.009%
6 Months
-99.578%
12 Months
-99.791%
Year To Date
-99.867%
All Time
-99.997%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
C
CDTX
0.72
(5.3973%)
USD
A
ADCT
-0.1
(-3.4247%)
USD
A
ALT
0.035
(0.3692%)
USD
C
CODX
-0.06
(-5.1724%)
USD
A
APT
-0.08
(-1.4953%)
USD
N
NVAX
-0.695
(-8.22%)
USD
V
VIR
-0.28
(-3.0238%)
USD
V
VXRT
-0.0067
(-0.9335%)
USD

Title:
Aditxt Inc

Sector:
Healthcare
Industry:
Biotechnology
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
Do you need help or have a question?
Contact Us